Our observation that reducing HDAC6 levels modulates the accumulation of poly (GA) in mice further suggests that HDAC6 knockdown could be beneficial in c9FTD/ALS, and that HDAC6 could be an interesting therapeutic target. The gene discussed is HDAC6; the disease is amyotrophic lateral sclerosis.